These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35184268)

  • 21. Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis.
    Fleischmann R; Furst DE
    Expert Opin Drug Saf; 2020 Aug; 19(8):935-944. PubMed ID: 32497440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
    Morris NT; Brook J; Ben-Artzi A; Martin W; Kermani TA; Avedikian-Tatosyan L; Karpouzas G; Nagam H; Navarro G; Choi S; Taylor MB; Elashoff D; Kaeley GS; Ranganath VK
    Clin Rheumatol; 2021 Dec; 40(12):5055-5065. PubMed ID: 34269927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repository Corticotropin Injection (Acthar
    Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
    Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis.
    Mäkinen H; Kautiainen H; Hannonen P; Möttönen T; Korpela M; Leirisalo-Repo M; Luukkainen R; Puolakka K; Karjalainen A; Sokka T
    J Rheumatol; 2007 Oct; 34(10):1987-91. PubMed ID: 17611990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
    Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA
    Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database.
    Ranganath VK; Paulus HE; Onofrei A; Khanna D; Reed G; Elashoff DA; Kremer JM; Furst DE
    J Rheumatol; 2008 Oct; 35(10):1966-71. PubMed ID: 18785317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data.
    Duong SQ; Crowson CS; Athreya A; Atkinson EJ; Davis JM; Warrington KJ; Matteson EL; Weinshilboum R; Wang L; Myasoedova E
    Arthritis Res Ther; 2022 Jul; 24(1):162. PubMed ID: 35778714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
    Philbin M; Niewoehner J; Wan GJ
    Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Atorvastatin on the Disease Activity and Severity of Rheumatoid Arthritis: Double-Blind Randomized Controlled Trial.
    Mowla K; Rajai E; Ghorbani A; Dargahi-Malamir M; Bahadoram M; Mohammadi S
    J Clin Diagn Res; 2016 May; 10(5):OC32-6. PubMed ID: 27437268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort.
    Geng Y; Han J; Deng X; Zhang Z
    Clin Rheumatol; 2014 Aug; 33(8):1061-6. PubMed ID: 24777468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort.
    Gamboa-Cárdenas RV; Ugarte-Gil MF; Loreto M; Sacnun MP; Saurit V; Cardiel MH; Soriano ER; Pisoni C; Galarza-Maldonado CM; Rios C; Radominski SC; Castelar-Pinheiro GDR; Bianchi WA; Appenzeller S; da Silveira IG; de Freitas Zerbini CA; Caballero-Uribe CV; Rojas-Villarraga A; Guibert-Toledano M; Ballesteros F; Montufar R; Vázquez-Mellado J; Esquivel-Valerio J; De La Torre IG; Barile-Fabris LA; Palezuelos FI; Andrade-Ortega L; Monge P; Teijeiro R; Achurra-Castillo ÁF; Esteva Spinetti MH; Alarcón GS; Pons-Estel BA
    Clin Rheumatol; 2019 Oct; 38(10):2737-2746. PubMed ID: 31161486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up.
    Manivel VA; Mullazehi M; Padyukov L; Westerlind H; Klareskog L; Alfredsson L; Saevarsdottir S; Rönnelid J
    Ann Rheum Dis; 2017 Sep; 76(9):1529-1536. PubMed ID: 28336519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept.
    Decker DA; Higgins P; Hayes K; Bollinger C; Becker P; Wright D
    BMC Musculoskelet Disord; 2020 Aug; 21(1):586. PubMed ID: 32867752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
    Taylor PC; Chen YF; Pope J; Weinblatt M; Mysler E; Rubbert-Roth A; Jia B; Sun L; Liu Y; Holzkämper T; Tanaka Y
    Rheumatol Ther; 2023 Apr; 10(2):463-476. PubMed ID: 36662442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(2):e001050. PubMed ID: 31908842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis.
    Pisaniello HL; Whittle SL; Lester S; Menz F; Metcalf R; McWilliams L; Hill CL; Proudman S
    BMC Rheumatol; 2022 Nov; 6(1):67. PubMed ID: 36376988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.